Literature DB >> 23483818

From fatty liver to fibrosis: a tale of "second hit".

Metin Basaranoglu1, Gökcen Basaranoglu, Hakan Sentürk.   

Abstract

Although much is known about how fat accumulates in the liver, much remains unknown about how this causes sustained hepatocellular injury. The consequences of injury are recognized as nonalcoholic steatohepatitis (NASH) and progressive fibrosis. The accumulation of fat within the hepatocytes sensitizes the liver to injury from a variety of causes and the regenerative capacity of a fatty liver is impaired. An additional stressor is sometimes referred to as a "second hit" in a paradigm that identifies the accumulation of fat as the "first hit". Possible candidates for the second hit include increased oxidative stress, lipid peroxidation and release of toxic products such as malondialdehyde and 4-hydroxynonenal, decreased antioxidants, adipocytokines, transforming growth factor (TGF)-β, Fas ligand, mitochondrial dysfunction, fatty acid oxidation by CYPs (CYP 2E1, 4A10 and 4A14), and peroxisomes, excess iron, small intestinal bacterial overgrowth, and the generation of gut-derived toxins such as lipopolysaccharide and ethanol. Oxidative stress is one of the most popular proposed mechanisms of hepatocellular injury. Previous studies have specifically observed increased plasma and tissue levels of oxidative stress markers and lipid peroxidation products, with reduced hepatic and plasma levels of antioxidants. There is also some indirect evidence of the benefit of antioxidants such as vitamin E, S-adenosylmethionine, betaine, phlebotomy to remove iron, and N-acetylcysteine in NASH. However, a causal relationship or a pathogenic link between NASH and oxidative stress has not been established so far. A number of sources of increased reactive oxygen species production have been established in NASH that include proinflammatory cytokines such as tumor necrosis factor (TNF)-α, iron overload, overburdened and dysfunctional mitochondria, CYPs, and peroxisomes. Briefly, the pathogenesis of NASH is multifactorial and excess intracellular fatty acids, oxidant stress, ATP depletion, and mitochondrial dysfunction are important causes of hepatocellular injury in the steatotic liver.

Entities:  

Keywords:  Fatty liver; Fibrosis; Nonalcoholic fatty liver diseases; Nonalcoholic steatohepatitis; Oxidative stress

Mesh:

Substances:

Year:  2013        PMID: 23483818      PMCID: PMC3587471          DOI: 10.3748/wjg.v19.i8.1158

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  70 in total

1.  Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis.

Authors:  A Sonsuz; M Basaranoglu; G Ozbay
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

2.  Is liver fibrosis reversible?

Authors:  P A Bonis; S L Friedman; M M Kaplan
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

3.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

4.  Reliability of caspase activity as a biomarker of hepatic apoptosis in nonalcoholic fatty liver disease.

Authors:  Billur Canbakan; Hakan Senturk; Mustafa Canbakan; Tayfur Toptas; Murat Tuncer
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

5.  Weight gain induced by high-fat feeding involves increased liver oxidative stress.

Authors:  Fermín I Milagro; Javier Campión; J Alfredo Martínez
Journal:  Obesity (Silver Spring)       Date:  2006-07       Impact factor: 5.002

Review 6.  Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis.

Authors:  Metin Basaranoglu; Gökcen Basaranoglu
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

7.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

8.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.

Authors:  Boris Hansel; Philippe Giral; Estelle Nobecourt; Sandrine Chantepie; Eric Bruckert; M John Chapman; Anatol Kontush
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

9.  Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.

Authors:  Veysel Tahan; Billur Canbakan; Huriye Balci; Faysal Dane; Hakan Akin; Guray Can; Ibrahim Hatemi; Vakur Olgac; Abdullah Sonsuz; Gulsen Ozbay; Ibrahim Yurdakul; Hakan Senturk
Journal:  Hepatogastroenterology       Date:  2008 Jul-Aug

10.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.

Authors:  Laura H Tetri; Metin Basaranoglu; Elizabeth M Brunt; Lisa M Yerian; Brent A Neuschwander-Tetri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

View more
  62 in total

Review 1.  Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emer ging Role of Lipin-1.

Authors:  Min You; Alvin Jogasuria; Kwangwon Lee; Jiashin Wu; Yanqiao Zhang; Yoon Kwang Lee; Prabodh Sadana
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 2.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 3.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

4.  Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria.

Authors:  Joanna M Lotowska; Maria E Sobaniec-Lotowska; Sylwia B Bockowska; Dariusz M Lebensztejn
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 5.  Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction.

Authors:  Metin Basaranoglu; Gokcen Basaranoglu; Elisabetta Bugianesi
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

Review 6.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

Review 7.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 8.  Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.

Authors:  Long-Xin Qiu; Tong Chen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

9.  Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Authors:  Colin T Shearn; Blair Fennimore; David J Orlicky; Yue R Gao; Laura M Saba; Kayla D Battista; Stefanos Aivazidis; Mohammed Assiri; Peter S Harris; Cole Michel; Gary F Merrill; Edward E Schmidt; Sean P Colgan; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2019-08-01       Impact factor: 7.376

10.  Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis.

Authors:  Ryan E Feaver; Banumathi K Cole; Mark J Lawson; Stephen A Hoang; Svetlana Marukian; Brett R Blackman; Robert A Figler; Arun J Sanyal; Brian R Wamhoff; Ajit Dash
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.